NASDAQ:SGEN - Seagen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $179.64
  • Forecasted Upside: 5.59 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▼ -3.9 (-2.24%)

This chart shows the closing price for SGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Seagen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGEN

Analyst Price Target is $179.64
▲ +5.59% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Seagen in the last 3 months. The average price target is $179.64, with a high forecast of $220.00 and a low forecast of $145.00. The average price target represents a 5.59% upside from the last price of $170.14.

This chart shows the closing price for SGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 contributing investment analysts is to buy stock in Seagen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 1 sell ratings
  • 1 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/29/2022Royal Bank of CanadaBoost Price Target$136.00 ➝ $179.00Low
7/29/2022Morgan StanleyBoost Price TargetOverweight$180.00 ➝ $181.00Low
7/27/2022Needham & Company LLCBoost Price TargetBuy$180.00 ➝ $188.00Low
7/27/2022HC WainwrightBoost Price TargetBuy$170.00 ➝ $200.00Low
7/19/2022GuggenheimSet Price Target$204.00Low
7/15/2022Morgan StanleyBoost Price TargetOverweight$173.00 ➝ $180.00Low
7/8/2022JMP SecuritiesBoost Price TargetMarket Outperform$157.00 ➝ $196.00N/A
6/29/2022Raymond JamesInitiated CoverageOutperform$220.00Low
6/23/2022BMO Capital MarketsInitiated CoverageMarket Perform$169.00Low
6/21/2022OppenheimerBoost Price TargetOutperform$160.00 ➝ $208.00Low
6/8/2022JMP SecuritiesReiterated RatingBuy$157.00Low
6/6/2022SVB LeerinkBoost Price TargetOutperform$155.00 ➝ $159.00Low
5/24/2022JMP SecuritiesReiterated RatingBuy$157.00Low
4/18/2022JMP SecuritiesReiterated RatingBuy$157.00Low
4/12/2022Morgan StanleyBoost Price TargetOverweight$170.00 ➝ $173.00Medium
2/16/2022JMP SecuritiesLower Price TargetMarket Outperform$201.00 ➝ $142.00Low
2/11/2022OppenheimerLower Price Target$198.00 ➝ $162.00Medium
2/10/2022Stifel NicolausLower Price Target$180.00 ➝ $145.00High
2/10/2022Wolfe ResearchLower Price TargetPeer Perform$195.00 ➝ $146.00High
2/10/2022Bank of AmericaLower Price TargetBuy$210.00 ➝ $170.00High
2/10/2022Royal Bank of CanadaLower Price TargetSector Perform$154.00 ➝ $132.00High
2/10/2022Morgan StanleyLower Price TargetOverweight$175.00 ➝ $170.00High
2/10/2022SVB LeerinkLower Price TargetOutperform$179.00 ➝ $155.00High
2/10/2022HC WainwrightLower Price TargetBuy$200.00 ➝ $170.00High
2/10/2022Piper SandlerLower Price TargetNeutral$165.00 ➝ $150.00High
2/7/2022Needham & Company LLCLower Price TargetBuy$254.00 ➝ $200.00High
1/31/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$178.00 ➝ $175.00High
1/18/2022Morgan StanleyLower Price TargetEqual Weight$181.00 ➝ $178.00Medium
12/14/2021JMP SecuritiesReiterated RatingBuy$201.00Low
11/8/2021Wolfe ResearchInitiated CoverageMarket Perform$195.00High
10/29/2021Morgan StanleyBoost Price TargetEqual Weight$167.00 ➝ $181.00Low
10/29/2021OppenheimerBoost Price TargetOutperform$196.00 ➝ $198.00High
10/28/2021Piper SandlerBoost Price TargetNeutral$160.00 ➝ $165.00High
10/27/2021SVB LeerinkBoost Price TargetOutperform$190.00 ➝ $200.00Low
9/27/2021Royal Bank of CanadaBoost Price TargetSector Perform$148.00 ➝ $154.00Low
9/22/2021SVB LeerinkLower Price TargetOutperform$192.00 ➝ $190.00Medium
9/20/2021Piper SandlerReiterated RatingHold$160.00High
7/16/2021Morgan StanleyLower Price TargetEqual Weight$173.00 ➝ $167.00Medium
5/17/2021Evercore ISIInitiated CoverageInline$153.00Low
4/30/2021Needham & Company LLCInitiated CoverageBuy$254.00High
4/30/2021Piper SandlerLower Price TargetIn-Line ➝ Neutral$170.00 ➝ $160.00High
3/30/2021Credit Suisse GroupInitiated CoverageNeutral$145.00Medium
2/16/2021Royal Bank of CanadaLower Price TargetSector Perform$186.00 ➝ $169.00Low
2/12/2021Morgan StanleyLower Price TargetEqual Weight$177.00 ➝ $173.00Low
2/12/2021SVB LeerinkLower Price TargetOutperform$200.00 ➝ $192.00Low
2/12/2021HC WainwrightReiterated RatingBuyLow
2/12/2021Berenberg BankReiterated RatingBuyLow
2/12/2021BarclaysLower Price TargetEqual Weight$177.00 ➝ $168.00Low
2/12/2021Piper SandlerLower Price TargetIn-Line ➝ Neutral$175.00 ➝ $170.00Low
2/9/2021William BlairReiterated RatingOutperformLow
2/1/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$188.00 ➝ $186.00Low
1/19/2021Morgan StanleyBoost Price TargetEqual Weight$175.00 ➝ $177.00Low
1/15/2021Bank of AmericaUpgradeNeutral ➝ Buy$215.00High
11/17/2020Needham & Company LLCReiterated RatingBuy$254.00Medium
10/30/2020Morgan StanleyBoost Price TargetEqual Weight$167.00 ➝ $175.00High
10/30/2020SVB LeerinkLower Price TargetOutperform$204.00 ➝ $200.00High
10/22/2020OppenheimerInitiated CoverageBuy$213.00Medium
10/16/2020William BlairReiterated RatingBuyMedium
10/15/2020Bank of AmericaBoost Price TargetNeutral$180.00 ➝ $215.00Low
10/13/2020JMP SecuritiesBoost Price TargetPositive ➝ Outperform$200.00 ➝ $216.00Medium
10/12/2020SVB LeerinkBoost Price TargetOutperform$187.00 ➝ $204.00Medium
9/22/2020JMP SecuritiesBoost Price Target$185.00 ➝ $200.00Low
9/22/2020Stifel NicolausBoost Price TargetHold$145.00 ➝ $165.00Low
9/22/2020SVB LeerinkBoost Price TargetOutperform$185.00 ➝ $187.00Low
9/18/2020Needham & Company LLCInitiated CoverageBuy$188.00Low
9/16/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
9/15/2020SVB LeerinkBoost Price TargetOutperform$173.00 ➝ $185.00Medium
9/15/2020Morgan StanleyBoost Price TargetEqual Weight$160.00 ➝ $167.00Medium
9/14/2020Royal Bank of CanadaBoost Price TargetOutperform$175.00 ➝ $191.00Medium
7/31/2020Morgan StanleyBoost Price TargetEqual Weight$149.00 ➝ $160.00High
7/31/2020SVB LeerinkBoost Price TargetOutperform$167.00 ➝ $173.00Low
7/31/2020HC WainwrightReiterated RatingBuy$175.00 ➝ $200.00Low
7/24/2020Piper SandlerDowngradeOverweight ➝ Neutral$155.00 ➝ $165.00Low
7/2/2020William BlairReiterated RatingBuyLow
6/30/2020BMO Capital MarketsBoost Price Target$174.00 ➝ $186.00High
6/30/2020SVB LeerinkBoost Price TargetOutperform$155.00 ➝ $167.00Low
6/30/2020Needham & Company LLCBoost Price TargetBuy$163.00 ➝ $188.00Low
6/26/2020OppenheimerBoost Price TargetPositive ➝ Outperform$175.00 ➝ $200.00High
5/31/2020OppenheimerInitiated CoverageBuy$146.00 ➝ $175.00Medium
5/26/2020JMP SecuritiesInitiated CoverageOutperform$185.00High
5/26/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
5/4/2020Morgan StanleyBoost Price TargetEqual Weight$111.00 ➝ $149.00High
5/3/2020BarclaysReiterated RatingNeutral ➝ HoldHigh
5/1/2020CfraBoost Price TargetSell$122.00 ➝ $129.00High
5/1/2020Stifel NicolausBoost Price TargetHold$120.00 ➝ $127.00High
5/1/2020Royal Bank of CanadaBoost Price TargetOutperform$148.00 ➝ $149.00High
5/1/2020SVB LeerinkBoost Price TargetOutperform$146.00 ➝ $155.00High
5/1/2020Needham & Company LLCBoost Price TargetBuy$157.00 ➝ $163.00High
5/1/2020HC WainwrightBoost Price TargetBuy$150.00 ➝ $175.00High
5/1/2020GuggenheimUpgradeNeutral ➝ BuyHigh
4/27/2020Piper SandlerBoost Price TargetOverweight$135.00 ➝ $155.00Low
4/20/2020BMO Capital MarketsBoost Price TargetOutperform$139.00 ➝ $154.00Medium
4/20/2020SVB LeerinkBoost Price TargetOutperform$138.00 ➝ $146.00Low
4/20/2020Stifel NicolausBoost Price TargetHold$103.00 ➝ $120.00Medium
4/20/2020OppenheimerBoost Price TargetOutperform$124.00 ➝ $146.00Low
4/20/2020Needham & Company LLCBoost Price TargetPositive ➝ Buy$144.00 ➝ $157.00Medium
4/20/2020Royal Bank of CanadaBoost Price TargetOutperform$121.00 ➝ $147.00High
4/20/2020Piper SandlerBoost Price TargetOverweight$125.00 ➝ $135.00High
4/19/2020Royal Bank of CanadaReiterated RatingBuyHigh
4/15/2020Morgan StanleyBoost Price TargetEqual Weight$107.00 ➝ $111.00Medium
4/3/2020William BlairReiterated RatingBuyLow
3/3/2020William BlairReiterated RatingOutperformMedium
2/18/2020BarclaysDowngradeOverweight ➝ Equal Weight$124.00Medium
2/12/2020HC WainwrightReiterated RatingBuy$140.00 ➝ $150.00Low
2/11/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
2/11/2020The Goldman Sachs GroupBoost Price TargetBuy$126.00 ➝ $165.00Low
2/7/2020Piper SandlerLower Price Target$125.00Low
2/7/2020William BlairReiterated RatingOutperformHigh
2/7/2020Needham & Company LLCReiterated RatingBuy$135.00High
1/27/2020BMO Capital MarketsInitiated CoverageOutperform$139.00Medium
1/27/2020Royal Bank of CanadaReiterated RatingBuy$113.00Medium
1/17/2020Morgan StanleyLower Price TargetEqual Weight$123.00 ➝ $115.00Low
1/2/2020GuggenheimDowngradeBuy ➝ NeutralHigh
12/22/2019CowenReiterated RatingHold$100.00Medium
12/20/2019Piper Jaffray CompaniesBoost Price TargetOverweight$120.00 ➝ $130.00High
12/19/2019William BlairReiterated RatingBuyMedium
12/19/2019Stifel NicolausBoost Price Target$87.00 ➝ $101.00High
12/13/2019William BlairReiterated RatingBuyLow
12/13/2019HC WainwrightReiterated RatingBuy$140.00Medium
12/12/2019OppenheimerBoost Price TargetOutperform$110.00 ➝ $124.00Low
12/12/2019Needham & Company LLCReiterated RatingBuy$130.00High
12/10/2019Morgan StanleyInitiated CoverageEqual ➝ Equal Weight$123.00Low
12/3/2019Bank of AmericaInitiated CoverageNeutral$125.00High
10/31/2019BarclaysReiterated RatingBuy$117.00Low
10/30/2019Piper Jaffray CompaniesBoost Price TargetOverweight$120.00Medium
10/25/2019William BlairReiterated RatingBuyLow
10/22/2019Royal Bank of CanadaBoost Price TargetOutperform$80.00 ➝ $109.00Low
10/22/2019Deutsche Bank AktiengesellschaftBoost Price TargetHold$88.00 ➝ $95.00Low
10/22/2019SVB LeerinkBoost Price TargetOutperform ➝ Positive$102.00 ➝ $120.00Medium
10/22/2019OppenheimerBoost Price TargetOutperform$92.00 ➝ $110.00Medium
10/22/2019GuggenheimBoost Price TargetBuy ➝ Outperform$95.00 ➝ $120.00Low
10/22/2019Bank of AmericaBoost Price TargetUnderperform$58.00 ➝ $83.00Low
10/22/2019HC WainwrightReiterated RatingBuy$98.00 ➝ $140.00Medium
10/21/2019Piper Jaffray CompaniesSet Price TargetBuy$95.00Low
10/21/2019Needham & Company LLCSet Price TargetBuy$121.00Low
10/21/2019CowenSet Price TargetHold$80.00Low
10/21/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
10/2/2019Deutsche Bank AktiengesellschaftBoost Price TargetHold$79.00 ➝ $88.00Low
10/1/2019OppenheimerBoost Price TargetOutperform$82.00 ➝ $92.00Low
9/30/2019Needham & Company LLCSet Price TargetBuy$81.00Low
9/30/2019Stifel NicolausSet Price TargetHold$74.00Low
9/30/2019SVB LeerinkSet Price TargetBuy$102.00Low
9/30/2019CowenSet Price TargetHold$80.00High
9/29/2019Piper Jaffray CompaniesBoost Price TargetOverweight$75.00 ➝ $95.00High
9/27/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
9/27/2019Bank of AmericaSet Price TargetSell$58.00Low
9/27/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$78.00 ➝ $100.00High
9/12/2019OppenheimerUpgradeMarket Perform ➝ Outperform$77.00 ➝ $82.00Medium
8/26/2019BTIG ResearchInitiated CoverageNeutralLow
7/19/2019William BlairReiterated RatingBuyLow
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold ➝ Hold$79.00Medium
7/17/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$64.00 ➝ $75.00High
6/5/2019William BlairReiterated RatingBuyLow
4/28/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
4/26/2019HC WainwrightReiterated RatingBuyMedium
4/10/2019Stifel NicolausInitiated CoverageHold$70.00Medium
4/5/2019Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$89.00 ➝ $90.00Low
3/28/2019Piper Jaffray CompaniesReiterated RatingHoldMedium
3/27/2019Berenberg BankInitiated CoverageBuy ➝ Buy$95.00Medium
3/25/2019William BlairReiterated RatingOutperformLow
2/8/2019HC WainwrightReiterated RatingBuy$98.00High
2/7/2019Piper Jaffray CompaniesLower Price TargetNeutral$64.00High
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
10/26/2018BarclaysLower Price TargetOverweight ➝ Overweight$95.00 ➝ $90.00High
10/26/2018Needham & Company LLCLower Price TargetBuy$73.00High
10/26/2018Bank of AmericaDowngradeNeutral ➝ UnderperformHigh
10/26/2018HC WainwrightReiterated RatingBuy$98.00High
10/25/2018Piper Jaffray CompaniesLower Price TargetNeutral$66.00High
10/3/2018BarclaysBoost Price TargetPositive ➝ Overweight$80.00 ➝ $95.00Medium
10/2/2018Royal Bank of CanadaBoost Price TargetOutperform$98.00Low
9/26/2018JPMorgan Chase & Co.Reiterated RatingBuy$85.00Low
9/24/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$101.00Medium
9/17/2018GuggenheimInitiated CoverageBuyMedium
9/7/2018Piper Jaffray CompaniesReiterated RatingNeutral ➝ NeutralLow
7/30/2018Needham & Company LLCBoost Price TargetBuy$74.00 ➝ $79.00High
7/27/2018SunTrust BanksSet Price TargetBuy$81.00Low
7/27/2018BarclaysReiterated RatingBuy$80.00Low
7/27/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$66.00 ➝ $77.00High
7/27/2018Royal Bank of CanadaReiterated RatingBuy$75.00High
7/27/2018HC WainwrightReiterated RatingBuy$77.00 ➝ $98.00High
7/12/2018HC WainwrightReiterated RatingBuy$77.00Low
6/11/2018SunTrust BanksUpgradeHold ➝ Buy$60.00 ➝ $80.00Medium
6/5/2018HC WainwrightReiterated RatingBuyMedium
4/26/2018Cantor FitzgeraldSet Price TargetHold$50.00High
3/21/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$69.00 ➝ $67.00Low
3/20/2018Cantor FitzgeraldSet Price TargetHold$50.00Medium
3/20/2018Royal Bank of CanadaReiterated RatingBuy$73.00Medium
3/20/2018BarclaysInitiated CoverageOverweight ➝ Overweight$74.00High
3/13/2018CowenReiterated RatingHoldLow
2/14/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$60.00Low
2/7/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$70.00 ➝ $68.00Low
2/7/2018Needham & Company LLCReiterated RatingBuy ➝ Buy$72.00 ➝ $74.00High
2/7/2018SunTrust BanksReiterated RatingHold$60.00High
2/7/2018HC WainwrightReiterated RatingBuyHigh
2/1/2018HC WainwrightReiterated RatingBuy$75.00High
1/9/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
1/8/2018Cantor FitzgeraldSet Price TargetHold$50.00Low
1/2/2018OppenheimerReiterated RatingHoldHigh
12/12/2017Cantor FitzgeraldSet Price TargetHold$50.00Medium
12/11/2017CowenReiterated RatingHold$54.00Low
12/7/2017OppenheimerReiterated RatingHoldMedium
11/13/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$68.00 ➝ $69.00N/A
10/31/2017Morgan StanleyBoost Price TargetOverweight$64.00 ➝ $69.00N/A
10/30/2017JPMorgan Chase & Co.Boost Price TargetNeutral$55.00 ➝ $60.00N/A
10/29/2017CowenReiterated RatingHoldN/A
10/27/2017SunTrust BanksSet Price TargetHold$52.00N/A
10/27/2017HC WainwrightReiterated RatingBuy$75.00N/A
10/27/2017Bank of AmericaUpgradeUnderperform ➝ NeutralN/A
10/26/2017Jefferies Financial GroupReiterated RatingBuy$53.00N/A
10/23/2017GuggenheimReiterated RatingBuy ➝ Buy$72.00N/A
10/20/2017BarclaysUpgradeEqual Weight ➝ Overweight$60.00 ➝ $70.00N/A
10/16/2017BarclaysBoost Price TargetEqual Weight ➝ Equal Weight$55.00 ➝ $60.00N/A
10/10/2017Cantor FitzgeraldSet Price TargetHold$46.00N/A
10/10/2017OppenheimerInitiated CoverageHoldN/A
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$64.00N/A
10/4/2017SunTrust BanksReiterated RatingHold$45.00N/A
10/2/2017Cantor FitzgeraldSet Price TargetHold$46.00Medium
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$58.00Medium
9/14/2017Jefferies Financial GroupReiterated RatingBuy$53.00Low
9/8/2017OppenheimerReiterated RatingHoldLow
8/29/2017Cantor FitzgeraldReiterated RatingHoldMedium
8/16/2017Cantor FitzgeraldSet Price TargetHold$46.00Low
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 21 positive mentions
  • 12 negative mentions
  • 8 very negative mentions
  • 3 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 5 very negative mentions
  • 2 very positive mentions
  • 11 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
  • 7 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
  • 10 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 5 very negative mentions
  • 6 very positive mentions
  • 42 positive mentions
  • 1 negative mentions
  • 6 very negative mentions
  • 6 very positive mentions
  • 28 positive mentions
  • 8 negative mentions
  • 3 very negative mentions

Current Sentiment

  • 6 very positive mentions
  • 28 positive mentions
  • 8 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Seagen logo
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $170.14
Low: $164.81
High: $176.03

50 Day Range

MA: $169.57
Low: $139.40
High: $180.11

52 Week Range

Now: $170.14
Low: $105.43
High: $192.79


2,769,349 shs

Average Volume

1,219,536 shs

Market Capitalization

$31.38 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Seagen?

The following sell-side analysts have issued reports on Seagen in the last year: Bank of America Co., BMO Capital Markets, Guggenheim, HC Wainwright, JMP Securities, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Royal Bank of Canada, Stifel Nicolaus,, SVB Leerink LLC, TheStreet, and Wolfe Research.
View the latest analyst ratings for SGEN.

What is the current price target for Seagen?

14 Wall Street analysts have set twelve-month price targets for Seagen in the last year. Their average twelve-month price target is $179.64, suggesting a possible upside of 5.6%. Raymond James has the highest price target set, predicting SGEN will reach $220.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $145.00 for Seagen in the next year.
View the latest price targets for SGEN.

What is the current consensus analyst rating for Seagen?

Seagen currently has 4 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SGEN will outperform the market and that investors should add to their positions of Seagen.
View the latest ratings for SGEN.

What other companies compete with Seagen?

How do I contact Seagen's investor relations team?

Seagen's physical mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company's listed phone number is (425) 527-4000 and its investor relations email address is [email protected] The official website for Seagen is Learn More about contacing Seagen investor relations.